Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (COVID-19)

This Drug Safety Update discusses recent guidance issued for specialists to support adherence to the pregnancy prevention requirements for girls and women of childbearing potential taking valproate during the pandemic, particularly those shielding due to other health conditions.

SPS commentary:

The specialist advice is available at the link below. Annual reviews should not be delayed during the pandemic, and should be undertaken via video or telephone, in line with the process detailed on the guidance. When pregnancy testing is required, home testing could be acceptable, provided the minimum stated criteria are met.


Medicines and Healthcare products Regulatory Agency

Resource links:

Specialist guidance